I understand that Rubraca is targeting BRCA-mutated metastatic cancer that Xtandi and Zytiga no longer has an effect on.  Just thinking about how this relates to what ZEN-3694 is attempting to do.  Clovis is due to present at European Society of Medical Oncology in mid Oct. They are also working alongside Opdivo in triple negative breast cancer - another area where Zenith was planning on going into.

I hope we're not too late to the party, since it seems PARP inhibitors are gaining a lot of attention. 

https://www.fiercepharma.com/marketing/clovis-rubraca-pulls-ahead-parp-rivals-prostate-cancer-breakthrough-nod?mkt_tok=eyJpIjoiWTJJeVlUVXhaR016TXpVMCIsInQiOiJMc3BNWFVhVFAweEpZUmhXK1NiTmJqMUZqSmNmVlpxcjlmY3l2cUptcFwvN01ZT0pLbVhUQVlabEZ6Um5RSmVhZGdmbkdVUGZCNHJ5UXhoK2hCK3p2SHZzdHJLZStCN0Z4YXFLNmo2TVM4RXN6MEk1ZlBzOE9oV0JcL1diazVcL3g5RiJ9&mrkid=9803146 

masila